The Rise of Orphan Drugs for Rare Diseases

Jaime Rosenberg
May 7, 2018

During a session at the Academy of Managed Care Pharmacy’s Managed Care & Specialty Pharmacy Annual Meeting held April 23-26, in Boston, Massachusetts, Stephen Chung, PharmD, BCPS, manager, drug information, MedImpact Healthcare Systems, provided an in-depth look at the Orphan Drug Designation program through the progress that’s been made, recent changes, and challenges patients continue to face.

The Orphan Drug Designation program provides orphan status to drugs and biologics defined as those intended for the safe and effective treatment, diagnosis, or prevention of rare diseases. A rare disease is defined as one that affects less than 200,000 people in the United States or one that affects more than 200,000 people but the sponsors are not expected to recover the costs of developing a new drug.

“This program was first permitted to really address an unmet need, and that need is that there was not a sufficient incentive to develop in this area, and with that, that program itself has been remarkably successful” said Chung. “If you consider that this legislation was passed in 1983, since then there have been over 600 orphan drug approvals. In contrast, during the preceding decade, there were fewer than 10.”

Chung highlighted that the number of approvals has increased remarkably over the last few the years. A significant proportion of approvals in 2017 were related to oncology, with PD-1 and PD-L1 inhibitors accounting for several indications alone.

When Scott Gottlieb, MD, was appointed FDA Commissioner, one of the major priorities he wanted to address was the backlog of orphan drug requests, explain Chung. At the time, there were over 200 designation requests under review. In less than half a year, the agency was able to work through the entire backlog. While it doesn’t mean that all the requests were approved, they were all reviewed.

Moving forward, to avoid any further accumulation of backlog, the agency aims to complete reviews within 90 days. “I think you can expect to see the approval pick up some steam,” said Chung.

Chung also highlighted another change stemming from the FDA. In December 2017, the FDA issued draft guidance that it will no longer grant orphan drug designations to pediatric subpopulations unless: the disease in the pediatric population constitutes a valid orphan subset, and the drug meets all the other criteria for orphan drug designation; or the sponsor can adequately demonstrate that the disease in the pediatric subpopulation presents differently than in the adult population, and the drug meets all other criteria for orphan designation.

Chung concluded the session by highlighting issues that patients continue to face when accessing orphan drugs. Payer sensitivity to the cost of orphan drugs continues to rise, with annual costs in the range of hundreds of thousands of dollars per patient and few (if any) available alternative therapies.
As a result, payers have changed benefit designs to manage utilization and spend through several measures: formulary restrictions and specialty tiering, the shifting from co-payments to coinsurance, and prior authorization. An analysis of reimbursement data found that orphan drugs currently have more coverage restrictions than non-orphan drugs, and prior authorization is the more commonly technique used to implement restrictions.